Compare GGAL & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGAL | BIO |
|---|---|---|
| Founded | 1905 | 1952 |
| Country | Argentina | United States |
| Employees | 10098 | 7450 |
| Industry | Commercial Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.1B |
| IPO Year | N/A | N/A |
| Metric | GGAL | BIO |
|---|---|---|
| Price | $42.93 | $269.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $69.00 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.2M | 269.9K |
| Earning Date | 03-07-2023 | 04-30-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.99 | $2.74 |
| Revenue Next Year | N/A | $3.05 |
| P/E Ratio | $13.36 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.89 | $211.43 |
| 52 Week High | $66.24 | $343.12 |
| Indicator | GGAL | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 47.03 |
| Support Level | $40.54 | $266.71 |
| Resistance Level | $45.86 | $289.61 |
| Average True Range (ATR) | 2.15 | 7.96 |
| MACD | 0.32 | 1.32 |
| Stochastic Oscillator | 37.90 | 57.07 |
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.